JPS63183518A - Composition for hair - Google Patents
Composition for hairInfo
- Publication number
- JPS63183518A JPS63183518A JP22749487A JP22749487A JPS63183518A JP S63183518 A JPS63183518 A JP S63183518A JP 22749487 A JP22749487 A JP 22749487A JP 22749487 A JP22749487 A JP 22749487A JP S63183518 A JPS63183518 A JP S63183518A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- group
- formula
- composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 claims abstract description 18
- 239000011714 flavin adenine dinucleotide Substances 0.000 claims abstract description 18
- -1 adenosine 3',5'-cyclic-phosphate compound Chemical class 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 239000000126 substance Substances 0.000 claims abstract description 12
- 125000002252 acyl group Chemical group 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 8
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 8
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims abstract description 5
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims abstract description 4
- 150000001768 cations Chemical class 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 1
- 210000004761 scalp Anatomy 0.000 abstract description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 6
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 23
- 239000011734 sodium Substances 0.000 description 21
- 235000015961 tonic Nutrition 0.000 description 17
- 230000001256 tonic effect Effects 0.000 description 17
- 239000000839 emulsion Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000006071 cream Substances 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000003779 hair growth Effects 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 229960000716 tonics Drugs 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003676 hair preparation Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150109517 Camlg gene Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- XLRHXNIVIZZOON-WFUPGROFSA-L Flavin adenine dinucleotide disodium Chemical compound [Na+].[Na+].C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 XLRHXNIVIZZOON-WFUPGROFSA-L 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HTLLYOHOBDOWRT-UHFFFAOYSA-N ethane;hydroxy phosphono hydrogen phosphate Chemical compound CC.OOP(O)(=O)OP(O)(O)=O HTLLYOHOBDOWRT-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 206010020917 hypervitaminosis D Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
- A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、頭皮に外用することにより、毛根のメラノサ
イトを活性化し、メラニン生成を促進して白髪を防止、
改善することができる毛髪用組成物、例えばヘアトニッ
クなどに関するものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention is applied externally to the scalp to activate melanocytes in the hair roots, promote melanin production, and prevent gray hair.
It relates to hair compositions, such as hair tonics, which can be improved.
育毛・養毛剤についてはこれまでに数多くの開発がなさ
れているが、白髪の防止、改善効果を有する毛髪化粧料
については、開発結果の報告が極めて少ないのが現状で
ある。このうち、特開昭６０−１７４７’０５号には、
ビタミンＤ３及びその誘導体を利用することが記載され
ている。しかしながら、この方法には、
（ｉ）使用するビタミンＤ３及びその誘導体が、空気中
では極めて不安定で酸化されやすいために製剤化が困難
であり、外用剤として連用した場合、十分な効果を発揮
し得ない、
（ｉｉ）ビタミンＤ、及びその誘導体は、ビタミンＤ過
剰症、即ち、高カルシウム血症の症状（食欲不振、嘔吐
、便秘、体重減少、成長停止等）を起こす恐れがあり、
安全性の上の疑念がある、等の問題があり、該公開公報
記載の技術は実用性に乏しかった。Although a large number of hair growth and tonics have been developed to date, there are currently very few reports on the development results of hair cosmetics that have the effect of preventing or improving gray hair. Among them, JP-A-60-1747'05 has
The use of vitamin D3 and its derivatives has been described. However, this method has the following drawbacks: (i) Vitamin D3 and its derivatives used are extremely unstable in the air and easily oxidized, making it difficult to formulate formulations; however, when used continuously as an external preparation, it is not sufficiently effective; (ii) Vitamin D and its derivatives may cause symptoms of hypervitaminosis D, that is, hypercalcemia (anorexia, vomiting, constipation, weight loss, growth arrest, etc.);
There were problems such as doubts about safety, and the technology described in the publication was not practical.
従って、本発明は、頭皮に外用することにより、優れた
白髪防止、改善効果を発揮し、皮膚に対する安全性が極
めて高い毛髪用組成物を提供することを目的とする。Therefore, an object of the present invention is to provide a hair composition that exhibits excellent gray hair prevention and improvement effects when applied externally to the scalp and is extremely safe for the skin.
本発明は、生体内の各組織、細胞に微量に存在し、種々
の調節機能、生理作用を有する特定核酸関連物質及びそ
の誘導体を化粧料基材に含有させると上記問題点を有効
に解決できるとの知見に基づいてなされたものである。The present invention can effectively solve the above problems by incorporating specific nucleic acid-related substances and derivatives thereof, which exist in trace amounts in each tissue and cell in the living body and have various regulatory functions and physiological effects, into a cosmetic base material. This was done based on the knowledge that
すなわち、本発明は、下記［Ｉ］式で示される基本骨格
を有する化合物、フラビンアデニンジヌクレオチド及び
その塩からなる群から選ばれる少なくとも１種の核酸関
連物質を含有することを特徴とする毛髪用組成物を提供
する。That is, the present invention provides a hair product containing at least one nucleic acid-related substance selected from the group consisting of a compound having a basic skeleton represented by the following formula [I], flavin adenine dinucleotide, and salts thereof. A composition is provided.
本発明では、上記一般式〔■〕で表わされる骨格を分子
内に有する限りどのような化合物をも使用することがで
きるが、これらのうち下記一般式〔■〕で表わされる化
合物を用いるのが好ましい。In the present invention, any compound can be used as long as it has a skeleton represented by the above general formula [■] in the molecule, but among these, the compound represented by the following general formula [■] is preferred. preferable.
（式〔■〕中、Ｒ１、Ｒ２、Ｒ３は、水素、炭素数１〜
２２、好ましくは１〜１５のアシル基又は炭素数１〜２
２、好ましくは１〜１５のアルキル基であり、Ｘｌ、Ｘ
２は、水素、臭素、沃素、塩素、弗素などのハロゲン、
メルカプト基、炭素数１〜４のチオアルキル基、４−ク
ロロフェニルチオ基、チオベンジル基等のチオ含有基、
アミノ基、炭素数１〜４のアミノアルキル基又は水酸基
である。又、Ｍｌ は、水素や塩形成カチオン、例えば
ナトリウム、カリウム、リチウムなどのアルカリ金属、
トリス（ヒドロキシメチル）アミノメタンを示す。尚、
アシル基、アルキル基にはハロゲン等の置換基があって
もよく、芳香族環を含んでいてもよい。また、二塩基酸
由来のアシル基でもよい。）
上記一般式〔■〕で表わされる化合物には、アデノシン
３’、５’−環状一リン酸（式中、Ｒ１、Ｒ２、Ｒ３、
ｘｌ、ｘ２、ＭＩがいずれも水素の化合物；以下ｃＡＭ
Ｐと略称する。）、その特定の誘導体及びその塩が包含
される。(In formula [■], R1, R2, R3 are hydrogen, carbon number 1-
22, preferably 1 to 15 acyl group or carbon number 1 to 2
2, preferably an alkyl group of 1 to 15, Xl, X
2 is halogen such as hydrogen, bromine, iodine, chlorine, fluorine,
Thio-containing groups such as mercapto group, thioalkyl group having 1 to 4 carbon atoms, 4-chlorophenylthio group, thiobenzyl group,
They are an amino group, an aminoalkyl group having 1 to 4 carbon atoms, or a hydroxyl group. Ml also represents hydrogen, salt-forming cations, such as alkali metals such as sodium, potassium, and lithium;
Indicates tris(hydroxymethyl)aminomethane. still,
The acyl group and the alkyl group may have a substituent such as a halogen, and may contain an aromatic ring. Alternatively, it may be an acyl group derived from a dibasic acid. ) The compound represented by the above general formula [■] includes adenosine 3',5'-cyclic monophosphate (in the formula, R1, R2, R3,
A compound in which xl, x2, and MI are all hydrogen; hereinafter referred to as cAM
It is abbreviated as P. ), certain derivatives thereof and salts thereof.
次に、これらの化合物及びフラビンアデニンジヌクレオ
チド（以下ＦＡＤと略称する。）及びその塩について詳
しく説明する。Next, these compounds, flavin adenine dinucleotide (hereinafter abbreviated as FAD), and salts thereof will be explained in detail.
一般式［ＩＤで表わされる化合物
本発明で用いるｃＡＭＰは、生体内において、各種ホル
モン作用の調節機能を有する生理的に重要な物質であり
、すでに生化学試薬、心臓薬として利用されている。Compound represented by the general formula [ID] cAMP used in the present invention is a physiologically important substance that has the ability to regulate various hormone actions in vivo, and has already been used as a biochemical reagent and a cardiac drug.
現在、工業的には醗酵法または合成法で製造されている
が、さらに細胞膜透過性が改善された、あるいは生体内
での安定性が向上された各種誘導体も市販されている。Currently, they are produced industrially by fermentation or synthesis methods, but various derivatives with improved cell membrane permeability or in vivo stability are also commercially available.
本発明で用いる一般式〔■〕で表わされる化合物として
、具体的には、表−１に示される化合物とそれらのナト
リウム塩、カリウム塩、リチウム塩等の１種又は２種以
上の混合物が例示される。Specific examples of the compound represented by the general formula [■] used in the present invention include one or a mixture of two or more of the compounds shown in Table 1 and their sodium salts, potassium salts, lithium salts, etc. be done.
なお、表−１において用いたｃ ｐ ｐｈｓは、４−ク
ロロフェニルチオ基を表わす（以下、同じ）。Note that c p phs used in Table 1 represents a 4-chlorophenylthio group (the same applies hereinafter).
これらの化合物のうち、式〔■〕中のＲ１−Ｒ３、ｘｌ
、Ｘ２のすべてが水素でない化合物が好ましい。さらに
、Ｒ，、Ｒ３は水素またはアシル基、Ｒ２、ｘｌは水素
、ｘ２は水素、ハロゲン、チオ含有基、アミン基または
水酸基であるものが好ましい。これらのうち、特に好ま
しいのは、Ｘ２が水素の場合には、Ｒ＋ ＳＲａのいず
れか一方または両方ともがアシル基であって、該アシル
基がモノカルボン酸由来のものについては、炭素数５〜
１５のものが好ましく、ジカルボン酸由来のものについ
ては、炭素数２〜１５のものが好ましい。Among these compounds, R1-R3, xl in formula [■]
, X2 are all not hydrogen. Furthermore, it is preferable that R,, R3 are hydrogen or an acyl group, R2 and xl are hydrogen, and x2 is hydrogen, a halogen, a thio-containing group, an amine group, or a hydroxyl group. Among these, when X2 is hydrogen, one or both of R+SRa is an acyl group, and when the acyl group is derived from a monocarboxylic acid, it is particularly preferable that the acyl group has 5 to 5 carbon atoms.
Those having 15 carbon atoms are preferred, and those derived from dicarboxylic acids are preferably those having 2 to 15 carbon atoms.
また、Ｘ２がハロゲン、チオ含有基、アミノ基または水
酸基の場合には、Ｒ，、Ｒ３は水素または炭素数１〜１
５のアシル基であるものが好ましい。In addition, when X2 is a halogen, a thio-containing group, an amino group, or a hydroxyl group, R, R3 is hydrogen or has 1 to 1 carbon atoms.
5 is preferably an acyl group.
ＦＡＤ及びその塩
ＦＡＤは、酸化還元酵素の補酵素として、生体内で有機
化合物の酸化全般に関与する重要な物質として知られて
いる。そして、ＦＡＤは、医薬品原料として皮膚炎、ア
レルギー性疾患、口内炎、脚気の治療、さらに目薬の有
効成分等として広く用いられている。FAD and its salt FAD are known as important substances that are involved in the general oxidation of organic compounds in vivo as coenzymes of oxidoreductases. FAD is widely used as a pharmaceutical raw material in the treatment of dermatitis, allergic diseases, stomatitis, and beriberi, and as an active ingredient in eye drops.
現在、ＦＡＤは工業的に醗酵法または合成法で製造され
ており、容易に入手することが可能である。Currently, FAD is produced industrially by fermentation or synthesis, and is easily available.
尚、ＦＡＤの塩も本発明では使用可能であり、具体的に
はＦＡＤナトリウム塩（ＦＡＤ ・２Ｎａ） 、ＦＡ
Ｄカリウム塩（ＦＡＤ ・２Ｋ）などが例示される。Note that salts of FAD can also be used in the present invention, specifically FAD sodium salt (FAD 2Na), FA
Examples include D potassium salt (FAD 2K).
本発明では、必須成分とする前記核酸関連物質を頭皮に
直接族することにより、白髪防止、改善効果を発揮する
という、従来知られていなかった効果を利用するもので
あり、毛髪用組成物中に任意の濃度で配合できる。通常
は、製品形態、使用頻度にもよるが、各種毛髪用組成物
中にｏ、 ｏ ｏ ｉ〜５重量％（以下、％と略する。The present invention takes advantage of the hitherto unknown effect of preventing and improving gray hair by directly applying the nucleic acid-related substance as an essential ingredient to the scalp. Can be blended at any concentration. Usually, depending on the product form and frequency of use, various hair compositions contain o, o o i to 5% by weight (hereinafter abbreviated as %).
）程度、好ましくは０．０１〜２％配合するのがよい。), preferably 0.01 to 2%.
本発明の組成物には、上記の必須成分に加えて他の薬剤
成分として、例えばビタミンＡ１ビタミンＢ６ 、ビタ
ミンＥ１パントテン酸、ビオチン等のビタミン類、メチ
オニン、システィン、シスチン、チロシン等のアミノ酸
類、サリチル酸、ヒノキチオール、レゾルシン、トリク
ロロカルバニリド等の殺菌剤、エチニルエストラジオー
ル、プロゲステロン等のホルモン類等を配合することが
でき、好ましくは、毛髪用組成物中０．０００１〜３％
添加するのがよい。In addition to the above-mentioned essential ingredients, the composition of the present invention includes other pharmaceutical ingredients, such as vitamins such as vitamin A1, vitamin B6, vitamin E1, pantothenic acid, and biotin; amino acids such as methionine, cysteine, cystine, and tyrosine; Bactericidal agents such as salicylic acid, hinokitiol, resorcinol, trichlorocarbanilide, etc., hormones such as ethinyl estradiol, progesterone, etc. can be blended, and preferably 0.0001 to 3% in the hair composition.
It is good to add it.
さらに、油分、水、界面活性剤、保湿剤、低級アルコー
ル、増粘剤、酸化防止剤、キレート剤、ｐＨ調整剤、防
腐剤、香料、色素等通常化粧料に用いられる原料が配合
可能である。具体的には、油分としては、オリーブ油、
ホホバ油、硬化油等の油脂類、鯨ロウ、蜜ロウ、ラノリ
ン等のロウ類、流動パラフィン、セレシン、スクワラン
等の炭化水素類、ステアリン酸、オレイン酸等の脂肪酸
類、セタノール、ステアリルアルコール、ラノリンアル
コール、ヘキシルデカノール等のアルコール類、ミリス
チン酸イソプロピル、ステアリン酸ブチル等のエステル
類等である。油分を毛髪用組成物中０．５〜８５％含有
させるのがよい。また、界面活性剤としては、ステアリ
ン酸ナトリウム、セチル硫酸ナトリウム、ポリオキシエ
チレンラウリルエーテルリン酸、Ｎ−アシルグルタミン
酸ナトリウム等のアニオン界面活性剤、塩化ステアリル
ジメチルベンジルアンモニウム、塩化ステアリルトリメ
チルアンモニウム等のカチオン界面活性剤、塩酸アルキ
ルアミノエチルグリシン液、レシチン等の両性界面活性
剤、モノステアリン酸グリセリン、モノステアリン酸ソ
ルビタン、ショ糖脂肪酸エステル、モノステアリン酸プ
ロピレングリコール、ポリオキシエチレンオレイルエー
テル、モノステアリン酸ポリエチレングリコール、モノ
パルミチン酸ポリオキシエチレンソルビクン、ポリオキ
シエチレンヤシ脂肪酸モノエタノールアミド、ポリオキ
シエチレンポリオキシプロピレングリコール、ポリオキ
シエチレンヒマシ油、ポリオキシエチレンラノリン等の
非イオン界面活性剤等を例示することができる。界面活
性剤を毛髪用組成物中０．１〜１５％含有させるのがよ
い。さらに、保湿剤としては、グリセリン、１．３−ブ
チレングリコール、プロピレングリコール等を、低級ア
ルコールとしては、エタノール、インプロパツール等を
、増粘剤としては、ポリエチレングリコール、カルボキ
シメチルセルロースナトリウム等を、酸化防止剤として
は、ジブチルヒドロキシトルエン、ブチルヒドロキシア
ニソール、没食子酸プロピル等を、キレート剤としては
、エデト酸ニナトリウム、エタンヒドロキシジホスフェ
ート等を、ｐＨ調整剤としては、クエン酸、クエン酸ナ
トリウム、ホウ酸、ホウ砂、リン酸−水素ナトリウム等
を、防腐剤としては、パラオキシ安息香酸メチル、パラ
オキシ安息香酸エチノペデヒドロ酢酸、サリチル酸、安
息香酸等をそれぞれ例示することができる。なお、任意
成分は、これらに限定されるものではない。上記必須成
分と任意成分を適当に配合することにより、ヘアトニッ
ク、クリーム、ローション、乳液、軟膏等外用できる剤
型のものであればいずれでもよく、種々の製品形態で用
いることができる。Furthermore, raw materials commonly used in cosmetics such as oil, water, surfactants, humectants, lower alcohols, thickeners, antioxidants, chelating agents, pH adjusters, preservatives, fragrances, and pigments can be added. . Specifically, the oils include olive oil,
Oils and fats such as jojoba oil and hydrogenated oils, waxes such as spermaceti wax, beeswax, and lanolin, hydrocarbons such as liquid paraffin, ceresin, and squalane, fatty acids such as stearic acid and oleic acid, cetanol, stearyl alcohol, and lanolin. These include alcohols, alcohols such as hexyldecanol, and esters such as isopropyl myristate and butyl stearate. It is preferable that the hair composition contains oil in an amount of 0.5 to 85%. Examples of surfactants include anionic surfactants such as sodium stearate, sodium cetyl sulfate, polyoxyethylene lauryl ether phosphate, and sodium N-acylglutamate, and cationic surfactants such as stearyldimethylbenzylammonium chloride and stearyltrimethylammonium chloride. Active agent, alkylaminoethylglycine hydrochloride solution, amphoteric surfactant such as lecithin, glycerin monostearate, sorbitan monostearate, sucrose fatty acid ester, propylene glycol monostearate, polyoxyethylene oleyl ether, polyethylene glycol monostearate Examples include nonionic surfactants such as polyoxyethylene sorbicun monopalmitate, polyoxyethylene coconut fatty acid monoethanolamide, polyoxyethylene polyoxypropylene glycol, polyoxyethylene castor oil, and polyoxyethylene lanolin. can. The surfactant is preferably contained in the hair composition in an amount of 0.1 to 15%. Furthermore, as humectants, glycerin, 1,3-butylene glycol, propylene glycol, etc. are used, as lower alcohols, ethanol, inpropatol, etc. are used, as thickeners, polyethylene glycol, carboxymethyl cellulose sodium, etc., and oxidized As inhibitors, dibutylhydroxytoluene, butylhydroxyanisole, propyl gallate, etc. are used. As chelating agents, disodium edetate, ethane hydroxy diphosphate, etc. are used. As pH adjusters, citric acid, sodium citrate, boron, etc. are used. Examples of preservatives include methyl paraoxybenzoate, etinopedehydroacetic acid paraoxybenzoate, salicylic acid, and benzoic acid. Note that the optional components are not limited to these. By appropriately blending the above-mentioned essential components and optional components, it can be used in a variety of product forms, including hair tonics, creams, lotions, emulsions, ointments, etc., as long as they can be used externally.
具体的には、ヘアトニックとしては、上記必須成分０．
０１〜２％、低級アルコール４０〜９８％、薬剤成分０
〜３％、保湿剤０〜１５％、精製水０〜６０％、香料
微量を含有する組成物があげられ、ヘアクリームとして
は、上記必須成分０．０１〜２％、油分２０〜８０％、
界面活性剤０．５〜１５％、保湿剤０〜１５％、精製水
１５〜８０％、防腐剤微量を含有する組成物が例示され
る。また、乳液としては、上記必須成分０．０１〜２％
、油分５〜３０％、界面活性剤０．５〜１５％、保湿剤
０〜１５％、精製水５０〜９５％、防腐剤 微量を含有
する組成物が例示される。Specifically, the hair tonic contains 0.0% of the above essential ingredients.
01-2%, lower alcohol 40-98%, drug ingredients 0
~3%, moisturizer 0-15%, purified water 0-60%, fragrance
Examples include compositions containing trace amounts of the above essential ingredients, 0.01 to 2% of the above essential ingredients, 20 to 80% of oil content,
An example is a composition containing 0.5 to 15% surfactant, 0 to 15% humectant, 15 to 80% purified water, and a trace amount of preservative. In addition, as an emulsion, 0.01 to 2% of the above essential ingredients
Examples include compositions containing 5 to 30% oil, 0.5 to 15% surfactant, 0 to 15% humectant, 50 to 95% purified water, and a trace amount of preservative.
本発明で用いられる核酸関連物質が、外用により白髪防
止、改善効果を示す作用の詳細は不明であるが頭皮毛根
の毛球部に存在するメラノサイトを活性化してメラニン
生成を促進し、生成したメラニン顆粒が毛母細胞に取り
込まれることにより、白髪防止、改善効果が発揮され、
さらには、毛母細胞の賦活化等により養毛・育毛作用も
発揮されるものと推定される。The details of the effect of the nucleic acid-related substance used in the present invention on preventing and improving gray hair when applied externally are unknown, but it activates melanocytes present in the hair bulb of the scalp hair roots to promote melanin production, resulting in the production of melanin. By incorporating the granules into hair matrix cells, it has the effect of preventing and improving gray hair.
Furthermore, it is presumed that it also exhibits hair nourishing and restoring effects by activating hair matrix cells.
また、本発明の核酸関連物質は、本来生体内に広く存在
するものであることから、安全性は極めて高いが、念の
ため安全性について確認したところ、急性毒性、皮膚刺
激性、皮膚感作性等の点で実用上特に問題は認められな
かった。In addition, the nucleic acid-related substance of the present invention is extremely safe because it is widely present in living organisms. No practical problems were observed in terms of performance, etc.
本発明によれば、頭皮に外用することにより、優れた白
髪防止、改善効果を発揮し、皮膚に対する安全性が極め
て高い毛髪化粧料が提供される。According to the present invention, there is provided a hair cosmetic that exhibits excellent gray hair prevention and improvement effects when applied externally to the scalp and is extremely safe for the skin.
本発明によれば、養毛・育毛効果も上記効力に加えて、
発揮される。According to the present invention, in addition to the above-mentioned effects, hair nourishing and hair growth effects are also achieved.
Demonstrated.
゛ 従って本発明の毛髪用組成物は、毛髪に適用するた
めの種々の形態、例えばヘアトニック、クリーム、ロー
ション、乳液、軟膏、ヘアトリートメント、ヘアコンデ
ィショナー等の毛髪化粧料等、外用できる剤型のものと
して種々の形態で幅広く使用できる。Therefore, the hair composition of the present invention can be applied to hair in various forms, such as hair tonics, creams, lotions, emulsions, ointments, hair treatments, hair conditioners, and other hair cosmetics, and externally applicable formulations. It can be used widely in various forms.
次に、実施例により本発明を説明する。Next, the present invention will be explained by examples.
なお、実施例においては以下の略号を用いた。In addition, the following abbreviations were used in the examples.
ＭＢ：モノブチリル
ＭＨ：モノヘキサノイル
ＭＯ＝モノオクタノイル
ＭＳ：モノサクシニル
ＤＡニジアセチル
ＤＢニジブチリル
ＤＭ＝ジマロニル
ＤＳニジサクシニル
ＣβＰｈＳ：４−クロロフェニルチオ
また、ｃＡＭＰ誘導体の置換基の位置は次のように示し
た。MB: monobutyryl MH: monohexanoyl MO = monooctanoyl MS: monosuccinyl DA nidiacetyl DB nidibutyryl DM = dimalonyl DS nidisuccinyl CβPhS: 4-chlorophenylthio Further, the positions of the substituents of the cAMP derivative are shown as follows.
Ｎ６ ：Ｒ，またはＲ２が水素以外の場合の結合位置を
示す。N6: Indicates the bonding position when R or R2 is other than hydrogen.
０”：Ｒ３が水素以外の場合の結合位置を示す。0'': Indicates the bonding position when R3 is other than hydrogen.
８：Ｘ２が水素以外の場合の結合位置を示す。8: Shows the bonding position when X2 is other than hydrogen.
実施例１
エタノールに香料を加えて均一に溶解した。これとは別
に、精製水に他の成分を加えて均一に溶解した溶液を調
製しておき、ここに前記エタノール溶液を加えてヘアト
ニックを調製した。表−２に組成を示すが、表中の数値
は配合量（重量％）である（以下同じ）。Example 1 A fragrance was added to ethanol and dissolved uniformly. Separately, a solution was prepared by adding other ingredients to purified water and uniformly dissolved therein, and the ethanol solution was added thereto to prepare a hair tonic. The composition is shown in Table 2, and the numerical values in the table are the blending amount (% by weight) (the same applies hereinafter).
表−２
上記ヘアトニックを、白髪のある２０名の男女（３０〜
６０才）に１日２回（朝・夜）、連続３力月間、本発明
品と比較例のそれぞれをハーフ・ヘッド法で左右頭皮に
別々に使用させ、塗布部位の状態を、試験前後で比較し
、白髪防止、改善効果を調べた。結果を次に示す。Table 2 The above hair tonic was applied to 20 men and women with gray hair (30~
(60 years old) twice a day (morning and evening) for 3 consecutive months, the product of the present invention and the comparative example were used separately on the left and right scalp using the half-head method, and the condition of the application site was observed before and after the test. We compared the results and investigated their effectiveness in preventing and improving gray hair. The results are shown below.
表−３
表−３の結果から、Ｎ６．０” −ＤＢｃＡＭＰ−Ｎａ
を配合した本発明のヘアトニックは、無添加のヘアトニ
ックと比較して、白髪の量を少なくすることができ、顕
著な白髪防止・改善効果を示すことがわかる。Table-3 From the results of Table-3, N6.0''-DBcAMP-Na
It can be seen that the hair tonic of the present invention containing the above can reduce the amount of gray hair compared to a hair tonic without additives, and exhibits a remarkable effect of preventing and improving gray hair.
なお、上記ヘアトニックの３力月間の使用中及び使用後
においても、皮膚の状態に異常な症状は特に認められな
かった。In addition, no abnormal symptoms were observed in the skin condition during or after using the hair tonic for three months.
Ｎ６． Ｏ” −ＤＢｃＡＭＰ−Ｎａの安全性にツイテ
試験を行った。試験項目と結果をまとめて表−４に示す
。N6. A tweet test was conducted to check the safety of O''-DBcAMP-Na. The test items and results are summarized in Table 4.
表−４の結果からＮ６． Ｏ” −ＤＢｃＡＭＰ −Ｎ
ａの安全性は極めて高いことが確認された。From the results in Table-4, N6. O”-DBcAMP-N
It was confirmed that the safety of a was extremely high.
実施例２
表−５に示す成分１〜５及び成分６〜１０を別々に８０
℃にて加熱溶解した後、両者を混合乳化し、冷却中に、
成分１１を加え、さらに均一に分散して、毛髪用乳液を
調製した。尚、表中、Ｔはエチレンオキシドの平均付加
モル数を示す（以下、同じ）。Example 2 Components 1 to 5 and components 6 to 10 shown in Table 5 were separately prepared at 80%
After heating and dissolving at ℃, the two were mixed and emulsified, and while cooling,
Component 11 was added and further uniformly dispersed to prepare a hair emulsion. In addition, in the table, T indicates the average number of added moles of ethylene oxide (the same applies hereinafter).
表−５
実施例１と同様にして前記乳液の白髪防止、改善効果を
調べた。結果を表−６に示す。Table 5 In the same manner as in Example 1, the effect of the milky lotion on preventing and improving gray hair was investigated. The results are shown in Table-6.
表−６
表−６の結果から、ＦＡＤ ・２Ｎａを配合した本発
明の乳液を使用した場合は、無添加の乳液を使用した場
合に比べて、白髪の量が少なく、顕著な白髪防止、改善
効果を示した。Table 6 From the results in Table 6, when using the emulsion of the present invention containing FAD/2Na, the amount of gray hair was smaller than when using an additive-free emulsion, and there was significant prevention and improvement of gray hair. It was shown to be effective.
なお、上記乳液の３力月間の使用中及び使用後において
も、皮膚の状態に異常な症状は特に認められなかった。In addition, no abnormal skin symptoms were observed during or after using the emulsion for three months.
さらに、同じ乳液を用いて以下のように養毛効果につい
ても試験を行った。Furthermore, the same emulsion was also tested for hair growth effect as described below.
即ち、Ｃ５７ブラツクマウス６匹を１群とし、マウスの
腹部両側から背部にかけて刺毛し、片側に本発明の乳液
を、もう一方には比較例を毎日１回、連続２週間塗布し
た。そして、１週間毎に刺毛部に生えてきた毛の長さを
それぞれ測定して養毛効果を比較した。結果を表−７に
示す。尚、表２ °を
中の数値は毛の長さくｍｍ）を（平均値上標準偏差）で
示したものである。That is, six C57 black mice were made into one group, hairs were pricked from both sides of the abdomen to the back of the mice, and the emulsion of the present invention was applied to one side and the comparative example was applied once a day for two consecutive weeks for two consecutive weeks. Then, the length of hair that grew in the pricked area was measured every week to compare the hair growth effects. The results are shown in Table-7. The numerical values in Table 2 are the hair length (mm) expressed as the standard deviation above the average value.
表−７
表−７の結果から明らかなように、ＦＡＤ ・２Ｎａ
を配合した本発明の乳液は、無添加の乳液と比較して著
しい養毛効果を示した。Table 7 As is clear from the results in Table 7, FAD ・2Na
The emulsion of the present invention containing the above showed a remarkable hair-nourishing effect compared to the emulsion without additives.
ＦＡＤ ・２Ｎａの安全性について実施例１と同じ方
法で実験したところ、皮膚刺激等の問題点は全く認めら
れず、安全性は極めて高いことが確認された。When testing the safety of FAD 2Na using the same method as in Example 1, no problems such as skin irritation were observed, and it was confirmed that the safety was extremely high.
実施例３
表−８に示す成分１〜６及び成分７〜１０を別々に８０
℃で加熱溶解した後混合乳化し、冷却中に成分１１を加
え、均一に分散して表−８に示すヘアクリームを調製し
た。Example 3 Components 1 to 6 and components 7 to 10 shown in Table-8 were separately prepared at 80%
After heating and dissolving at ℃, the mixture was mixed and emulsified, and while cooling, component 11 was added and uniformly dispersed to prepare the hair cream shown in Table 8.
実施例１と同様にして、ヘアクリームの白髪防止、改善
効果を調べた。結果を表−９に示す。In the same manner as in Example 1, the effect of the hair cream on preventing and improving gray hair was investigated. The results are shown in Table-9.
表−９
表−９の結果からＮ６． Ｏ” −ＤＳｃＡＭＰ−Ｎａ
を配合した本発明のクリームを使用した場合は、無添加
のクリームを使用した場合に比べて、白髪の量が少なく
、顕著な白髪防止、改善効果を示した。Table-9 From the results of Table-9, N6. O”-DScAMP-Na
When the cream of the present invention containing the following was used, the amount of gray hair was smaller than when using a cream without additives, and it showed a remarkable effect of preventing and improving gray hair.
なお、上記クリームの３力月間の使用中及び使用後にお
いても、皮膚の状態に異常な症状は特に認められなかっ
た。又、Ｎ６．０” −ＤＳｃＡＭＰ−Ｎａの安全性に
ついて実施例１と同じ方法で実験したところ、皮膚刺激
等の問題点は全く認められず、安全性は極めて高いこと
が確認された。Furthermore, during and after using the above cream for three months, no abnormal symptoms were observed in the condition of the skin. Furthermore, when the safety of N6.0"-DScAMP-Na was tested in the same manner as in Example 1, no problems such as skin irritation were observed, and it was confirmed that the safety was extremely high.
実施例４
表−１０に示す成分１〜４及び成分５〜９を別々に混合
溶解した後、成分５〜９の溶液を撹拌しながら、ここに
成分１〜４の溶液を添加し、表−１０に示す毛髪用乳液
を調製した。Example 4 After separately mixing and dissolving components 1 to 4 and components 5 to 9 shown in Table 10, the solution of components 1 to 4 was added thereto while stirring the solution of components 5 to 9, and the solution of components 1 to 4 was added to the solution shown in Table 1. A hair emulsion shown in No. 10 was prepared.
実施例１と同様にして、乳液の白髪防止、改善効果を調
べた。結果を表−１１に示す。In the same manner as in Example 1, the effect of the emulsion on preventing and improving gray hair was investigated. The results are shown in Table-11.
表−１１
表−１１の結果からＯ” −ＭＳｃ、ＡＭＰ−Ｎａを配
合した本発明の乳液を使用した場合は、無添加の乳液を
使用した場合に比べて、白髪の量が少なく、顕著な白髪
防止、改善効果を示した。Table 11 From the results in Table 11, when using the emulsion of the present invention containing O"-MSc and AMP-Na, the amount of gray hair was less and more noticeable than when using an additive-free emulsion. It has been shown to be effective in preventing and improving gray hair.
なお、上記乳液の３力月間の使用中及び使用後において
も、皮膚の状態に異常な症状は特に認められなかった。In addition, no abnormal skin symptoms were observed during or after using the emulsion for three months.
又、Ｏ” −ＭＳｃＡＭＰ−Ｎａの安全性について実施
例１と同じ方法で実験したところ、皮膚刺激等の問題点
は全く認められず、安全性は極めて高いことが確認され
た。Furthermore, when testing the safety of O''-MScAMP-Na using the same method as in Example 1, no problems such as skin irritation were observed, and it was confirmed that the safety was extremely high.
実施例５
表−１２に示す組成のヘアクリームを調製し、実施例１
と同様にして、白髪防止、改善効果を調べた。結果を表
−１３に示す。Example 5 A hair cream having the composition shown in Table 12 was prepared, and Example 1
In the same manner as above, the effect of preventing and improving gray hair was investigated. The results are shown in Table-13.
表−１３
表−１３の結果から、Ｎ６−ＭＢｃＡＭＰ−Ｎａを配合
した本発明のヘアクリームを使用した場合は、無添加の
ヘアクリームを使用した場合に比べて、白髪の量が少な
く、顕著な白髪防止、改善効果を示した。
“
なお、上記ヘアクリームの３力月間の使用中及び使用後
においても、皮膚の状態に異常な症状は特に認められな
かった。又、Ｎ６−ＭＢｃＡＭＰ−Ｎａの安全性につい
て実施例１と同じ方法で実験したところ、皮膚刺激等の
問題点は全く認められず、安全性は極めて高いことが確
認された。Table 13 From the results in Table 13, when using the hair cream of the present invention containing N6-MBcAMP-Na, the amount of gray hair was less and more noticeable than when using additive-free hair cream. It has been shown to be effective in preventing and improving gray hair.
“In addition, no abnormal symptoms were observed in the skin condition during or after using the above hair cream for 3 months.In addition, the safety of N6-MBcAMP-Na was tested using the same method as in Example 1. When tested, no problems such as skin irritation were observed, confirming that the product is extremely safe.
実施例６
実施例３で用いたＮ６． Ｏ” −ＤＳｃＡＭｌ”Ｎａ
の代りに、８−ＢｒｃＡＭｔ’Ｎａ、 ８−Ｃ１２ｃＡ
ＭＰ−Ｎａ、 ８−Ｃｊｌ！ ＰｈＳｃＡＭＰ・Ｎａ、
８−３ｆｌ８−３ｆｌｃＡ、 ８−ＯＨｃ８−０Ｈｃ
Ａ、 Ｏ” −ＭＢ−８−ＢｒｃＡＭＰ・ＮａまたはＮ
６．０” −Ｄ＾−８−ＮＨ２ＣＡＭＰ−Ｎａを配合し
たヘアトニックを調製し、実施例１と同様にして評価し
たところ、実施例３とほぼ同等の白髪防止、改善効果が
得られた。Example 6 N6. used in Example 3. O”-DScAMl”Na
instead of 8-BrcAMt'Na, 8-C12cA
MP-Na, 8-Cjl! PhScAMP・Na,
8-3fl8-3flcA, 8-OHc8-0Hc
A, O”-MB-8-BrcAMP・Na or N
A hair tonic containing 6.0"-D^-8-NH2CAMP-Na was prepared and evaluated in the same manner as in Example 1. As a result, almost the same gray hair prevention and improvement effect as in Example 3 was obtained.
実施例７
エタノールに他の成分を順次加えて均一に溶解し、ヘア
トニックを調製した。組成を表−１４に示す。Example 7 A hair tonic was prepared by sequentially adding other ingredients to ethanol and uniformly dissolving them. The composition is shown in Table-14.
表−１４
実施例１と同様にして、前記ヘアトニックの白髪防止、
改善効果を調べた。結果を表−１５に示す。Table 14 In the same manner as in Example 1, the hair tonic was used to prevent gray hair,
The improvement effect was investigated. The results are shown in Table-15.
表−１５
表−１５の結果から、ＦＡＤ・２Ｎａを配合した本発明
のヘアトニックを使用した場合は、無添加のヘアトニッ
クを使用した場合に比べて、白髪の量が少なく、顕著な
白髪防止、改善効果を示した。Table 15 From the results in Table 15, when using the hair tonic of the present invention containing FAD/2Na, the amount of gray hair was smaller than when using the hair tonic without additives, and there was significant prevention of gray hair. , showed an improvement effect.
なお、上記ヘアトニックの３力月間の使用中及び使用後
においても、皮膚の状態に異常な症状は特１こδ忍めら
れなかった。Furthermore, even during and after using the above hair tonic for three months, I could not bear any unusual symptoms in my skin condition.
実施例８
実施例７で用いたＦＡＤ・２Ｎａの代りに、Ｎａ−ＭＳ
ｃＡＭｌ”Ｎａ、％Ｎ６−ＭＨｃＡＭＰ−Ｎａ、 ０”
−ＭＯｃＡＭＰ−ＮａまたはＮａ、 Ｏ”−ＤＭｃＡ
Ｍｔ’Ｎａを配合したヘアトニックを調製し、実施例１
と同様にして評価したところ、実施例７とほぼ同等の白
髪防止、改善効果が得られた。Example 8 Instead of FAD・2Na used in Example 7, Na-MS
cAMl”Na, %N6-MHcAMP-Na, 0”
-MOcAMP-Na or Na, O”-DMcA
A hair tonic containing Mt'Na was prepared and Example 1
When evaluated in the same manner as in Example 7, almost the same gray hair prevention and improvement effects as in Example 7 were obtained.
Claims (2)
物、フラビンアデニンジヌクレオチド及びその塩からな
る群から選ばれる少なくとも１種の核酸関連物質を含有
することを特徴とする毛髪用組成物。 ▲数式、化学式、表等があります▼・・・・・・〔 I
〕(1) A hair composition comprising at least one nucleic acid-related substance selected from the group consisting of a compound having a basic skeleton represented by the following formula [I], flavin adenine dinucleotide, and salts thereof. ▲There are mathematical formulas, chemical formulas, tables, etc.▼・・・・・・〔I
]
、下記一般式〔II〕で表わされるアデノシン３′，５′
−環状−リン酸化合物である特許請求の範囲第（１）項
記載の毛髪用組成物。 ▲数式、化学式、表等があります▼・・・・・・〔II〕 （式〔II〕中、Ｒ＿１、Ｒ＿２、Ｒ＿３は、水素、炭素
数１〜２２のアシル基または炭素数１〜２２のアルキル
基であり、Ｘ＿１およびＸ＿２は、水素、ハロゲン、チ
オ含有基、アミノ基、アミノアルキル基または水酸基で
あり、Ｍ＿１は、水素または塩形成カチオンを示す。）(2) The compound having the basic skeleton represented by the formula [I] is adenosine 3',5' represented by the following general formula [II]
- The hair composition according to claim (1), which is a cyclic phosphoric acid compound. ▲There are mathematical formulas, chemical formulas, tables, etc.▼・・・・・・[II] (In the formula [II], R_1, R_2, R_3 are hydrogen, an acyl group having 1 to 22 carbon atoms, or an acyl group having 1 to 22 carbon atoms. is an alkyl group, X_1 and X_2 are hydrogen, halogen, thio-containing group, amino group, aminoalkyl group or hydroxyl group, and M_1 represents hydrogen or a salt-forming cation.)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22021186 | 1986-09-18 | ||
| JP61-220211 | 1986-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63183518A true JPS63183518A (en) | 1988-07-28 |
Family
ID=16747628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP22749487A Pending JPS63183518A (en) | 1986-09-18 | 1987-09-10 | Composition for hair |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63183518A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001773A1 (en) * | 1993-07-07 | 1995-01-19 | Trustees Of Boston University | Stimulation of tanning by dna fragments |
| US6103689A (en) * | 1994-08-31 | 2000-08-15 | Trustees Of Boston University | Methods of inducing hair growth and coloration |
| US6867179B1 (en) | 1994-08-31 | 2005-03-15 | Trustees Of Boston University | Methods of inducing hair growth and coloration |
| US7196055B2 (en) | 1994-08-31 | 2007-03-27 | Trustees Of Boston University | Inhibition of apoptosis in keratinocytes by a ligand of p75 nerve growth factor receptor |
| JP2009534334A (en) * | 2006-04-21 | 2009-09-24 | ディーエスエム アイピー アセッツ ビー．ブイ． | Use of opioid receptor antagonists |
| JP2010229071A (en) * | 2009-03-26 | 2010-10-14 | Kose Corp | Oil-based solid hair cosmetic |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2077725A1 (en) * | 1970-02-10 | 1971-11-05 | Lapinet Eugene | Adenosine phosphoric acid - to stimulate cellular function of the ski |
| DE2139183A1 (en) * | 1971-08-05 | 1973-02-15 | Lingner Werke Gmbh | Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid |
| JPS6245527A (en) * | 1985-08-21 | 1987-02-27 | Shiseido Co Ltd | Preventive and remedy for gray hair |
-
1987
- 1987-09-10 JP JP22749487A patent/JPS63183518A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2077725A1 (en) * | 1970-02-10 | 1971-11-05 | Lapinet Eugene | Adenosine phosphoric acid - to stimulate cellular function of the ski |
| DE2139183A1 (en) * | 1971-08-05 | 1973-02-15 | Lingner Werke Gmbh | Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid |
| JPS6245527A (en) * | 1985-08-21 | 1987-02-27 | Shiseido Co Ltd | Preventive and remedy for gray hair |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001773A1 (en) * | 1993-07-07 | 1995-01-19 | Trustees Of Boston University | Stimulation of tanning by dna fragments |
| US5470577A (en) * | 1993-07-07 | 1995-11-28 | Trustees Of Boston University | Stimulation of tanning by DNA fragments or single-stranded DNA |
| US5532001A (en) * | 1993-07-07 | 1996-07-02 | Trustees Of Boston University | Stimulation of tanning by DNA fragments or single-stranded DNA |
| US5580547A (en) * | 1993-07-07 | 1996-12-03 | Trustees Of Boston University | Stimulation of tanning by DNA fragments or single-stranded DNA |
| US5643556A (en) * | 1993-07-07 | 1997-07-01 | Trustees Of Boston University | Stimulation of tanning by DNA fragments or single-stranded DNA |
| US6103689A (en) * | 1994-08-31 | 2000-08-15 | Trustees Of Boston University | Methods of inducing hair growth and coloration |
| US6867179B1 (en) | 1994-08-31 | 2005-03-15 | Trustees Of Boston University | Methods of inducing hair growth and coloration |
| US7196055B2 (en) | 1994-08-31 | 2007-03-27 | Trustees Of Boston University | Inhibition of apoptosis in keratinocytes by a ligand of p75 nerve growth factor receptor |
| JP2009534334A (en) * | 2006-04-21 | 2009-09-24 | ディーエスエム アイピー アセッツ ビー．ブイ． | Use of opioid receptor antagonists |
| JP2010229071A (en) * | 2009-03-26 | 2010-10-14 | Kose Corp | Oil-based solid hair cosmetic |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS63152309A (en) | External preparation of skin | |
| JP2844103B2 (en) | External preparation for skin | |
| JPS6245527A (en) | Preventive and remedy for gray hair | |
| JPS63183518A (en) | Composition for hair | |
| JPH0745387B2 (en) | Hair growth and hair growth promoter | |
| EP0260697B1 (en) | Composition for application to hair | |
| JPS6127909A (en) | External drug for skin | |
| JPS6127914A (en) | Cosmetic | |
| JP2709513B2 (en) | Hair restoration | |
| JP2781982B2 (en) | External preparation for skin | |
| JPH01316308A (en) | Preventive for gray hair | |
| JP2001288045A (en) | Composition for scalp and hair | |
| JPH0354081B2 (en) | ||
| JPS617205A (en) | Cell activator | |
| JPH01275516A (en) | Dandruff-preventive agent and hair-cosmetic | |
| JP2000198718A (en) | External preparation for promoting blood circulation | |
| JPS617206A (en) | Cell activator | |
| JPH11302131A (en) | Cosmetic for scalp and hair | |
| JPH0425249B2 (en) | ||
| US5376643A (en) | Composition for application to hair | |
| JP2002332237A (en) | Skin care preparation | |
| JPS63183535A (en) | External preparation for skin | |
| JP3431913B2 (en) | Vascular endothelial cell growth factor production promoter and skin color improving agent | |
| JP3624318B2 (en) | Hair nourishing agent | |
| JP2609884B2 (en) | Skin cosmetics |